Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
316 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Myocardial Infarction - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Myocardial Infarction - Pipeline Review, H2 2014', provides an overview of the Myocardial Infarction's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Myocardial Infarction Overview 11 Therapeutics Development 12 Pipeline Products for Myocardial Infarction - Overview 12 Pipeline Products for Myocardial Infarction - Comparative Analysis 13 Myocardial Infarction - Therapeutics under Development by Companies 14 Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes 19 Myocardial Infarction - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Myocardial Infarction - Products under Development by Companies 25 Myocardial Infarction - Products under Investigation by Universities/Institutes 30 Myocardial Infarction - Companies Involved in Therapeutics Development 31 Sanofi 31 AstraZeneca PLC 32 Advanced Cell Technology, Inc. 33 Athersys, Inc. 34 GlaxoSmithKline plc 35 Merck & Co., Inc. 36 BioLineRx, Ltd. 37 FibroGen, Inc. 38 Laboratoires Pierre Fabre SA 39 Zydus Cadila Healthcare Limited 40 Hadasit Medical Research Services & Development Ltd 41 A. Menarini Industrie Farmaceutiche Riunite Srl 42 Bayer AG 43 Merck KGaA 44 Ligand Pharmaceuticals, Inc. 45 Lixte Biotechnology Holdings, Inc. 46 Mesoblast Limited 47 Compugen Ltd. 48 Cardio3 BioSciences SA 49 CSL Limited 50 NeoStem, Inc. 51 LG Life Sciences, Ltd. 52 Pluristem Therapeutics Inc. 53 Juventas Therapeutics, Inc. 54 Bharat Biotech International Limited 55 Omni Bio Pharmaceutical Inc. 56 Remedy Pharmaceuticals, Inc. 57 Fina Biotech 58 QUANTUM GENOMICS Corp. 59 Angion Biomedica Corp. 60 GliaMed, Inc. 61 TaiGen Biotechnology Co., Ltd. 62 Lacer, S.A. 63 ViroMed Co., Ltd. 64 Medestea Research & Production S.p.A. 65 Lee's Pharmaceutical Holdings Limited 66 Genextra S.p.a. 67 Vicore Pharma AB 68 Cellmid Limited 69 Saneron CCEL Therapeutics, Inc. 70 Serodus ASA 71 Targazyme, Inc. 72 Aprogen, Inc. 73 Amarantus Bioscience Holdings, Inc. 74 APT Therapeutics, Inc. 75 DecImmune Therapeutics, Inc. 76 Inbiopro Solutions Pvt. Ltd. 77 Immune Pharmaceuticals, Inc. 78 CellProthera SAS 79 Recardio GmbH 80 BEAT BioTherapeutics Corp. 81 Myocardial Infarction - Therapeutics Assessment 82 Assessment by Monotherapy Products 82 Assessment by Combination Products 83 Assessment by Target 84 Assessment by Mechanism of Action 88 Assessment by Route of Administration 92 Assessment by Molecule Type 94 Drug Profiles 97 THR-100 - Drug Profile 97 amediplase - Drug Profile 99 ticagrelor - Drug Profile 100 rivaroxaban - Drug Profile 103 clopidogrel bisulfate - Drug Profile 107 Bone Marrow Derived Mononuclear Cells for Cardiovascular Diseases - Drug Profile 109 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 111 BB-3 - Drug Profile 113 CSL-112 - Drug Profile 115 CEP-41750 - Drug Profile 116 losmapimod - Drug Profile 118 MTP-131 - Drug Profile 120 BQ-123 - Drug Profile 122 RNS-60 - Drug Profile 124 AMR-001 - Drug Profile 126 LC-280126 - Drug Profile 128 Autologous Myoblasts - Drug Profile 130 REC-01 - Drug Profile 132 CAP-1002 - Drug Profile 133 ZK-001 - Drug Profile 134 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 136 CTX-101 - Drug Profile 138 Stempeucel-AMI - Drug Profile 139 Alpha-1 Antitrypsin - Drug Profile 140 MultiStem - Drug Profile 141 Stem Cell Based Cardiac Therapy - Drug Profile 144 burixafor - Drug Profile 145 CIGB-500 - Drug Profile 147 Gene Therapy for Acute Myocardial Infarction - Drug Profile 148 FG-4539 - Drug Profile 149 GM-1485 - Drug Profile 150 CM-1 - Drug Profile 152 BL-7060 - Drug Profile 154 CGEN-856 - Drug Profile 156 rusalatide acetate - Drug Profile 157 CGEN-857 - Drug Profile 160 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 161 LB-100 - Drug Profile 163 JVS-100 - Drug Profile 165 Stromal-Derived Factor 1 for Cardiovascular Diseases - Drug Profile 167 C3BSGQR-1 - Drug Profile 168 glyburide - Drug Profile 169 HYPER-IL-6 - Drug Profile 172 CMK-103 - Drug Profile 173 Stem Cell Therapy for Blood and Cardiovascular Diseases - Drug Profile 174 LA-8045 - Drug Profile 175 AMRS-001 - Drug Profile 176 C-21 - Drug Profile 177 IBPB-005ET - Drug Profile 179 AP-102 - Drug Profile 180 ANG-4011 - Drug Profile 181 EP-1013 - Drug Profile 182 AS-605240 - Drug Profile 183 ICG-001 - Drug Profile 185 Autologous CD34 Stem Cells - Drug Profile 186 Intramyocardial Cardiospheres - Drug Profile 187 APT-102 - Drug Profile 188 JI-38 - Drug Profile 190 A-HSP27 - Drug Profile 191 Drugs to Inhibit Myosin for Cardiovascular Disorders - Drug Profile 192 Small Molecules to Inhibit mPTP for Cardiovascular and Neurodegenerative Diseases - Drug Profile 193 p66Shc Protein Inhibitors for Myocardial Infarction - Drug Profile 194 Conjugated Monoclonal Antibody Targeting hMR for Myocardial Infarction - Drug Profile 195 Adipose Tissue Derived Stem Cells - Drug Profile 196 Fc-Alpha-1 Antitrypsin - Drug Profile 197 Monoclonal Antibody to Inhibit CD20 for Cardiovascular Disease - Drug Profile 198 Messenger RNA Therapeutics for Cardiometabolic Diseases and Renal diseases - Drug Profile 199 TZ-101 - Drug Profile 200 N2 Antibody For Myocardial Infarction - Drug Profile 202 BBR-12 - Drug Profile 203 SER-130 - Drug Profile 204 Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile 205 Cell Therapy for Myocardial Infarction - Drug Profile 206 Human Pericytes + ckit Cardiac Progenitor Cells - Drug Profile 207 NL-005 - Drug Profile 208 FcAAT-3 - Drug Profile 209 FcAAT-2 - Drug Profile 210 C3BSGQR-4 - Drug Profile 212 AVE-0991 - Drug Profile 213 Biglycan Therapy for Cardiovascular Diseases - Drug Profile 214 Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 216 Iron Oxide Nanoparticles - Drug Profile 217 VN-100 - Drug Profile 218 Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction - Drug Profile 219 Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile 220 QGC-101 - Drug Profile 222 RNAi Oligonucleotide for Myocardial Infarction - Drug Profile 223 Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction - Drug Profile 224 Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile 225 Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 226 Proteins for Cardiovascular and Infectious Disease - Drug Profile 227 Small Molecules to Inhibit TNF-a for Cardiovascular and CNS Disorders - Drug Profile 228 Small Molecules for Myocardial Infarction - Drug Profile 229 Ephrin A-1 - Drug Profile 230 VM-202 - Drug Profile 231 Myocardial Infarction - Recent Pipeline Updates 233 Myocardial Infarction - Dormant Projects 299 Myocardial Infarction - Discontinued Products 301 Myocardial Infarction - Product Development Milestones 302 Featured News & Press Releases 302 Appendix 309 Methodology 309 Coverage 309 Secondary Research 309 Primary Research 309 Expert Panel Validation 309 Contact Us 310 Disclaimer 310
List of Tables Number of Products under Development for Myocardial Infarction, H2 2014 18 Number of Products under Development for Myocardial Infarction - Comparative Analysis, H2 2014 19 Number of Products under Development by Companies, H2 2014 21 Number of Products under Development by Companies, H2 2014 (Contd..1) 22 Number of Products under Development by Companies, H2 2014 (Contd..2) 23 Number of Products under Development by Companies, H2 2014 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H2 2014 26 Comparative Analysis by Late Stage Development, H2 2014 27 Comparative Analysis by Clinical Stage Development, H2 2014 28 Comparative Analysis by Early Stage Development, H2 2014 29 Comparative Analysis by Unknown Stage Development, H2 2014 30 Products under Development by Companies, H2 2014 31 Products under Development by Companies, H2 2014 (Contd..1) 32 Products under Development by Companies, H2 2014 (Contd..2) 33 Products under Development by Companies, H2 2014 (Contd..3) 34 Products under Development by Companies, H2 2014 (Contd..4) 35 Products under Investigation by Universities/Institutes, H2 2014 36 Myocardial Infarction - Pipeline by Sanofi, H2 2014 37 Myocardial Infarction - Pipeline by AstraZeneca PLC, H2 2014 38 Myocardial Infarction - Pipeline by Advanced Cell Technology, Inc., H2 2014 39 Myocardial Infarction - Pipeline by Athersys, Inc., H2 2014 40 Myocardial Infarction - Pipeline by GlaxoSmithKline plc, H2 2014 41 Myocardial Infarction - Pipeline by Merck & Co., Inc., H2 2014 42 Myocardial Infarction - Pipeline by BioLineRx, Ltd., H2 2014 43 Myocardial Infarction - Pipeline by FibroGen, Inc., H2 2014 44 Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H2 2014 45 Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 46 Myocardial Infarction - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2014 47 Myocardial Infarction - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 48 Myocardial Infarction - Pipeline by Bayer AG, H2 2014 49 Myocardial Infarction - Pipeline by Merck KGaA, H2 2014 50 Myocardial Infarction - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 51 Myocardial Infarction - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 52 Myocardial Infarction - Pipeline by Mesoblast Limited, H2 2014 53 Myocardial Infarction - Pipeline by Compugen Ltd., H2 2014 54 Myocardial Infarction - Pipeline by Cardio3 BioSciences SA, H2 2014 55 Myocardial Infarction - Pipeline by CSL Limited, H2 2014 56 Myocardial Infarction - Pipeline by NeoStem, Inc., H2 2014 57 Myocardial Infarction - Pipeline by LG Life Sciences, Ltd., H2 2014 58 Myocardial Infarction - Pipeline by Pluristem Therapeutics Inc., H2 2014 59 Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H2 2014 60 Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H2 2014 61 Myocardial Infarction - Pipeline by Omni Bio Pharmaceutical Inc., H2 2014 62 Myocardial Infarction - Pipeline by Remedy Pharmaceuticals, Inc., H2 2014 63 Myocardial Infarction - Pipeline by Fina Biotech, H2 2014 64 Myocardial Infarction - Pipeline by QUANTUM GENOMICS Corp., H2 2014 65 Myocardial Infarction - Pipeline by Angion Biomedica Corp., H2 2014 66 Myocardial Infarction - Pipeline by GliaMed, Inc., H2 2014 67 Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2014 68 Myocardial Infarction - Pipeline by Lacer, S.A., H2 2014 69 Myocardial Infarction - Pipeline by ViroMed Co., Ltd., H2 2014 70 Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H2 2014 71 Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 72 Myocardial Infarction - Pipeline by Genextra S.p.a., H2 2014 73 Myocardial Infarction - Pipeline by Vicore Pharma AB, H2 2014 74 Myocardial Infarction - Pipeline by Cellmid Limited, H2 2014 75 Myocardial Infarction - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2014 76 Myocardial Infarction - Pipeline by Serodus ASA, H2 2014 77 Myocardial Infarction - Pipeline by Targazyme, Inc., H2 2014 78 Myocardial Infarction - Pipeline by Aprogen, Inc., H2 2014 79 Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 80 Myocardial Infarction - Pipeline by APT Therapeutics, Inc., H2 2014 81 Myocardial Infarction - Pipeline by DecImmune Therapeutics, Inc., H2 2014 82 Myocardial Infarction - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 83 Myocardial Infarction - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 84 Myocardial Infarction - Pipeline by CellProthera SAS, H2 2014 85 Myocardial Infarction - Pipeline by Recardio GmbH, H2 2014 86 Myocardial Infarction - Pipeline by BEAT BioTherapeutics Corp., H2 2014 87 Assessment by Monotherapy Products, H2 2014 88 Assessment by Combination Products, H2 2014 89 Number of Products by Stage and Target, H2 2014 92 Number of Products by Stage and Mechanism of Action, H2 2014 96 Number of Products by Stage and Route of Administration, H2 2014 99 Number of Products by Stage and Molecule Type, H2 2014 102 Myocardial Infarction Therapeutics - Recent Pipeline Updates, H2 2014 239 Myocardial Infarction - Dormant Projects, H2 2014 305 Myocardial Infarction - Discontinued Products, H2 2014 307
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.